Vitrafy Life Sciences Limited (ASX:VFY)
Australia · Delayed Price · Currency is AUD 3.380
-0.170 (-4.79%)
Sep 15, 2026, 4:10 PM AEST
Vitrafy Life Sciences Revenue
In the fiscal year ending June 30, 2026, Vitrafy Life Sciences had annual revenue of 209.00K AUD, down -80.05%. Vitrafy Life Sciences had revenue of -1.77M in the half year ending June 30, 2026.
Revenue
209.00K
Revenue Growth
-80.05%
P/S Ratio
1,294.31
Revenue / Employee
n/a
Employees
n/a
Market Cap
270.51M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 209.00K | -838.75K | -80.05% |
| Jun 30, 2025 | 1.05M | -1.05M | -49.95% |
| Jun 30, 2024 | 2.09M | 37.10K | 1.80% |
| Jun 30, 2023 | 2.06M | 230.64K | 12.63% |
| Jun 30, 2022 | 1.83M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Cuscal | 597.20M |
| Tyro Payments | 488.73M |
| Aura Consolidated Group | 318.96M |
| FINEOS Corporation Holdings | 237.41M |
| EML Payments | 207.37M |
| Acusensus | 86.17M |
| Beforepay Group | 50.63M |
| Raiz Invest | 29.22M |
Vitrafy Life Sciences News
- 6 weeks ago - Vitrafy Life Sciences Earnings Call Transcript: H2 2026 - Transcripts
- 6 weeks ago - Vitrafy Life Sciences Slides: H2 2026 - Filings
- 6 weeks ago - Vitrafy Life Sciences Annual report: H2 2026 - Filings
- 3 months ago - Vitrafy Life Sciences Slides: Investor presentation - Filings
- 3 months ago - Vitrafy Life Sciences Slides: Investor presentation - Filings
- 3 months ago - Vitrafy Life Sciences Transcript: Study result - Transcripts
- 3 months ago - Vitrafy Life Sciences Slides: Study result - Filings
- 4 months ago - Vitrafy Life Sciences Earnings Call Transcript: Q3 2026 - Transcripts